Die 4 wichtigsten Arbeiten zu.....
Lopinavir/r (Kaletra®)
#153LB Efficacy of ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among Antiretroviral-naïve Women in Africa: OCTANE Trial 2/ACTG A5208
James McIntyre*1, M Hughes2, J Mellors3, Y Zheng2, J Hakim4, A Asmelash5, F Conradie6, R Schooley7, J Currier8, S Lockman2,5,9, and A5208/OCTANE Study Team
1Chris Hani Baragwanath Hosp, Johannesburg, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Pittsburgh Med Ctr, PA, US; 4Univ of Zimbabwe, Harare; 5Botswana-Harvard AIDS Inst, Gaborone; 6Univ of the Witwatersrand, Johannesburg, South Africa; 7Univ of California, San Diego, US; 8Univ of California, Los Angeles, US; and 9Brigham and Women`s Hosp, Boston, MA, US
#107LB Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study
Ole Kirk*1, A Mocroft2, P Reiss3, S De Wit4, D Sedlacek5, M Beniowski6, J Gatell7, A Phillips2, B Ledergerber8, J Lundgren1,9, and for the EuroSIDA Study Group
1Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; 2Royal Free and Univ Coll London Med Sch, UK; 3Academic Med Ctr, Univ of Amsterdam, The Netherlands; 4Ctr Hosp Univ Saint-Pierre, Brussels, Belgium; 5Charles Univ Hosp, Plzen, Czech Republic; 6Specialistic Hosp, Chorzow, Poland; 7Hosp Clin, Barcelona, Spain; 8Univ Hosp Zurich, Switzerland; and 9Rigshospitalet, Copenhagen, Denmark
# 620 Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Douglas Bruce*1, F Altice1, D Moody2, G Morse3, L Andrews1, S-N Lin2, W Fang2, Q Ma3, and G Friedland1
1Yale Univ AIDS Prgm, New Haven, CT, US; 2Univ of Utah, Salt Lake City, US; and 3Univ of Buffalo, NY, US
# 588 Adherence-resistance Relationships for Lopinavir/ritonavir (LPV/r)-based Regimens in Treatment-experienced Subjects
Martin King*, R Rode, T Podsadecki, A Lawal, L Fredrick, and B Bernstein
Abbott Labs, Abbott Park, IL, US
# 877 Pharmacokinetics of Lopinavir/Ritonavir Crushed vs Whole Tablets in Children
H Diep1, Brookie Best*1, E Capparelli1, S Rossi1, M Farrell1, E Williams2, G Lee2, J van den Anker2, and N Rakhmanina2
1Univ of California, San Diego, US and 2Children’s Natl Med Ctr, Washington, DC, US
Kollegen Fragen
